ST Shuang Cheng: The approval has been obtained from the Australian Therapeutic Goods Administration for the marketing of Icotapide Injection.

On the evening of May 19th, ST Shuangcheng announced that the company has recently received the listing approval for the injection of Exenatide issued by the Australian Therapeutic Goods Administration, with approved indications for use in patients undergoing non-emergency percutaneous coronary intervention with stent implantation; for the treatment of unstable angina or non-ST-segment elevation myocardial infarction patients.